- Home
- PRZO vs GTBP Comparison
PRZO vs GTBP Comparison
Compare PRZO & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- GTBP
- Stock Information
- Founded
- PRZO 2014
- GTBP 1965
- Country
- PRZO Israel
- GTBP United States
- Employees
- PRZO N/A
- GTBP N/A
- Industry
- PRZO
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- GTBP Health Care
- Exchange
- PRZO Nasdaq
- GTBP Nasdaq
- Market Cap
- PRZO 7.8M
- GTBP 6.8M
- IPO Year
- PRZO 2023
- GTBP N/A
- Fundamental
- Price
- PRZO $2.13
- GTBP $2.39
- Analyst Decision
- PRZO
- GTBP Strong Buy
- Analyst Count
- PRZO 0
- GTBP 1
- Target Price
- PRZO N/A
- GTBP $11.00
- AVG Volume (30 Days)
- PRZO 8.6M
- GTBP 1.3M
- Earning Date
- PRZO 09-03-2024
- GTBP 11-14-2024
- Dividend Yield
- PRZO N/A
- GTBP N/A
- EPS Growth
- PRZO N/A
- GTBP N/A
- EPS
- PRZO N/A
- GTBP N/A
- Revenue
- PRZO $558,382.00
- GTBP N/A
- Revenue This Year
- PRZO N/A
- GTBP N/A
- Revenue Next Year
- PRZO N/A
- GTBP N/A
- P/E Ratio
- PRZO N/A
- GTBP N/A
- Revenue Growth
- PRZO N/A
- GTBP N/A
- 52 Week Low
- PRZO $0.49
- GTBP $1.72
- 52 Week High
- PRZO $3.16
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- PRZO 56.32
- GTBP 42.95
- Support Level
- PRZO $1.77
- GTBP $2.32
- Resistance Level
- PRZO $2.00
- GTBP $2.63
- Average True Range (ATR)
- PRZO 0.32
- GTBP 0.27
- MACD
- PRZO -0.06
- GTBP -0.05
- Stochastic Oscillator
- PRZO 25.90
- GTBP 33.00
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the comapany applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.